Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income from Non-Controlling Interests (2016 - 2020)

Summit Therapeutics filings provide 7 years of Income from Non-Controlling Interests readings, the most recent being $6.3 million for Q1 2020.

  • Quarterly Income from Non-Controlling Interests fell 9.28% to $6.3 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$2.2 million through Mar 2020, down 10.3% year-over-year, with the annual reading at -$6.9 million for FY2019, 58.06% up from the prior year.
  • Income from Non-Controlling Interests hit $6.3 million in Q1 2020 for Summit Therapeutics, up from -$8.7 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $8.2 million in Q2 2018 and bottomed at -$16.4 million in Q1 2018.
  • Average Income from Non-Controlling Interests over 5 years is -$4.8 million, with a median of -$6.5 million recorded in 2017.
  • Peak annual rise in Income from Non-Controlling Interests hit 232.35% in 2018, while the deepest fall reached 342.04% in 2018.
  • Summit Therapeutics' Income from Non-Controlling Interests stood at -$5.8 million in 2016, then skyrocketed by 59.27% to -$2.3 million in 2017, then plummeted by 342.04% to -$10.4 million in 2018, then grew by 15.98% to -$8.7 million in 2019, then surged by 172.38% to $6.3 million in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Income from Non-Controlling Interests are $6.3 million (Q1 2020), -$8.7 million (Q4 2019), and $7.0 million (Q1 2019).